Éric Legouffe - Concepedia

Author

Éric Legouffe

Also Known As

E LEGOUFFE, E Legouffe, E. LEGOUFFE, E. Legouffe, Eric Legouffe, Legouffe Eric, Marielle Le Goff, Suzanne NGUYEN, Éric Legouffe

Publications

4.8K

Citations

H-Index

Concepts

All Affiliations

Inserm Hôpital Lapeyronie Centre Léon Bérard Hôpital Saint Eloi Assistance Publique – Hôpitaux de Paris

ÉL

About

Éric Legouffe is an author at Inserm specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	1.5K
2	Health Sciences	4	4	138
3	Blood Transplantation	2	2	59
4	Allergy	1	1	59
5	Anatomy	1	1	83

Éric Legouffe

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study Thomas Bachelot, C. Bourgier, Claire Cropet, Journal of Clinical Oncology	2012	707
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone Jérôme Moreaux, Éric Legouffe, Éric Jourdan, Blood	2003	559
Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial Bertrand Godeau, Sylvie Chevret, Bruno Varet, The Lancet ThrombosisAutoimmune DiseaseHigh-dose MethylprednisoloneIntravenous ImmunoglobulinImmunosuppressive Therapy	2002	264
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature Jérôme Moreaux, Friedrich W. Cremer, Thierry Rème, Blood	2005	257
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial Karim Fizazi, Laura Faivre, F. Lesaunier, The Lancet Oncology UrologyGetug 12Genitourinary CancerMedicineAndrogen Deprivation Therapy	2015	236
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial Sylvie Négrier, Gwénaëlle Gravis, David Pérol, The Lancet Oncology UrologyGenitourinary CancerMedicineRenal PathologyRandomised Phase 2	2011	236
CD200 is a new prognostic factor in multiple myeloma Jérôme Moreaux, Dirk Hose, Thierry Rème, Blood	2006	228
Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Laurence Albigès, Stéphane Oudard, Sylvie Négrier, Journal of Clinical Oncology	2012	162
Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations Emmanuelle Verger, Bruno Cassinat, Aurélie Chauveau, Blood	2015	154
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts Karin Tarte, John De Vos, Fenghuang Zhan, Blood	2002	147

Page 1